Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study. Clinics, [S. l.], v. 67, n. 3, p. 283–287, 2012. DOI: 10.6061/clinics/2012(03)14. Disponível em: https://www.revistas.usp.br/clinics/article/view/19668.. Acesso em: 14 may. 2024.